Drug Profile
Research programme: deubiquitylase enzyme inhibitors - Ubiquigent
Alternative Names: DUB protein inhibitorsLatest Information Update: 19 Oct 2022
Price :
$50
*
At a glance
- Originator Ubiquigent
- Class Small molecules
- Mechanism of Action Deubiquitinating enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 14 Oct 2022 FORMA Therapeutics has been acquired by Novo Nordisk
- 28 May 2022 No recent reports of development identified for research development in Neurodegenerative-disorders in Scotland
- 26 Oct 2021 Ubiquigent extended and expanded its collaboration with Bristol Myers Squibb for development of deubiquitylase (DUB) enzyme inhibitor